Davin MD - Augmedix Chief Officer
| AUGX Stock | USD 2.33 0.01 0.43% |
Insider
Davin MD is Chief Officer of Augmedix
| Address | 111 Sutter Street, San Francisco, CA, United States, 94104 |
| Phone | 888 669 4885 |
| Web | https://www.augmedix.com |
Augmedix Management Efficiency
The company has return on total asset (ROA) of (0.3061) % which means that it has lost $0.3061 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (3.2978) %, meaning that it created substantial loss on money invested by shareholders. Augmedix's management efficiency ratios could be used to measure how well Augmedix manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.3 in 2024. Return On Capital Employed is likely to drop to -0.46 in 2024. At this time, Augmedix's Net Tangible Assets are fairly stable compared to the past year. Non Current Assets Total is likely to rise to about 10.4 M in 2024, whereas Other Assets are likely to drop slightly above 954.4 K in 2024.Similar Executives
| Showing other executives | INSIDER Age | ||
| Trishna MD | In8bio Inc | 45 | |
| Ryan Bond | Aclarion | 52 | |
| Valerie MD | Elevation Oncology | 46 | |
| Gerald Proehl | Dermata Therapeutics | 65 | |
| RPh PharmD | Elevation Oncology | 40 | |
| Kenneth LaMontagne | In8bio Inc | N/A | |
| John Lorbiecki | Aclarion | 61 | |
| Brian Sullivan | Elevation Oncology | N/A | |
| Lawrence Lamb | In8bio Inc | 69 | |
| David Dornan | Elevation Oncology | 46 | |
| Ryan Bloomer | Elevation Oncology | N/A | |
| David Hale | Dermata Therapeutics | 75 | |
| William Ho | In8bio Inc | 45 | |
| TaiWei Ho | In8bio Inc | 47 | |
| Joseph Ferra | Elevation Oncology | 49 | |
| Kate Rochlin | In8bio Inc | 42 | |
Management Performance
| Return On Equity | -3.3 | ||||
| Return On Asset | -0.31 |
Augmedix Leadership Team
Elected by the shareholders, the Augmedix's board of directors comprises two types of representatives: Augmedix inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Augmedix. The board's role is to monitor Augmedix's management team and ensure that shareholders' interests are well served. Augmedix's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Augmedix's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Emmanuel Krakaris, CEO and President | ||
| Saurav Chatterjee, Chief Officer | ||
| Todd Holvick, Head Compliance | ||
| Jonathan Hawkins, Chief Officer | ||
| Tomer Levy, Senior Engineering | ||
| Lia Wallick, Head People | ||
| Davin MD, Chief Officer | ||
| Ian Shakil, Chief Founder | ||
| Paul Ginocchio, Chief Officer | ||
| Sandra Breber, Chief Officer |
Augmedix Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Augmedix a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -3.3 | ||||
| Return On Asset | -0.31 | ||||
| Profit Margin | (0.46) % | ||||
| Operating Margin | (0.64) % | ||||
| Current Valuation | 111.98 M | ||||
| Shares Outstanding | 49.43 M | ||||
| Shares Owned By Insiders | 6.53 % | ||||
| Shares Owned By Institutions | 85.14 % | ||||
| Number Of Shares Shorted | 1.32 M | ||||
| Price To Book | 10.97 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Augmedix Stock Analysis
When running Augmedix's price analysis, check to measure Augmedix's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Augmedix is operating at the current time. Most of Augmedix's value examination focuses on studying past and present price action to predict the probability of Augmedix's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Augmedix's price. Additionally, you may evaluate how the addition of Augmedix to your portfolios can decrease your overall portfolio volatility.